RSS SubscribeNew drug candidate treats severe fatty liver disease by improving gut health
From News Medical
Researchers discovered that a potential drug developed at Michigan Medicine treats severe fatty liver disease by improving gut health, according to a study published in The Journal of Clinical Investigation.
The glycine-based tripeptide, DT-109, reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models by disrupting a disease-driving pathway that links the gut and liver.
Legal Notice / Disclaimer
Ahead of the Herd newsletter, aheadoftheherd.com, hereafter known as AOTH.Please read the entire Disclaimer carefully before you use this website or read the newsletter. If you do not agree to all the AOTH/Richard Mills Disclaimer, do not access/read this website/newsletter/article, or any of its pages. By reading/using this AOTH/Richard Mills website/newsletter/article, and whether you actually read this Disclaimer, you are deemed to have accepted it.
Related posts
May 24, 2026
